SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlist is rallying significantly as investors capitalize on a monumental patent licensing and supply agreement with Samsung, which has bolstered the company's financial position and legal leverage against industry rivals. The community is buzzing with excitement over the stock trending on major platforms, with many retail investors holding firm, anticipating further settlements with other memory giants and a potential short squeeze as momentum continues to build.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is experiencing significant volatility following a Bank of America report highlighting massive off-balance-sheet financing obligations related to its AI platform, which has sparked investor anxiety regarding long-term debt and potential margin compression. Despite the selling pressure, the community remains divided, with many bulls dismissing the drop as a manipulation-driven shakeout while others express caution ahead of the company's upcoming earnings release.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is currently struggling to maintain a price floor above $1, fueling intense debate between retail investors bracing for further downside and those viewing current levels as a long-term accumulation opportunity. The community remains deeply divided, with many citing frustration over stalled adoption and price stagnation while others point to institutional interest and upcoming regulatory meetings as catalysts for a potential rebound.

Aventus Network

Aventus Network is facing intense community scrutiny and volatility following a sharp price decline and user reports of trading difficulties on Coinbase during a period of scheduled system maintenance. While some investors view the current low valuation as a speculative buying opportunity, others are expressing significant frustration over market manipulation concerns and the asset's overall stability.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending as traders digest a mix of an earnings miss and massive backlog expansion, fueling a volatile debate over whether the stock is primed for a long-term recovery or a continued short squeeze. The community remains deeply divided, with bulls pointing to the company's $1.8 billion contract backlog and institutional buying, while skeptical voices warn of ongoing share dilution and risks associated with future lunar mission execution.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is experiencing increased retail attention following the announcement of a partnership with TARA Mind to support patient recruitment for its Phase 3 HLP003 program, a key catalyst for upcoming data readouts. While community sentiment remains polarized between long-term bulls highlighting the potential of the drug's breakthrough designation and critics expressing concern over leadership turnover and cash burn, the stock is currently trending due to its role as a high-beta play within the evolving psychedelic therapeutic sector.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors digest the recent departure of longtime stakeholder Prem Watsa, which many in the community view as a positive catalyst that clears the path for potential institutional accumulation. Sentiment is heavily focused on BlackBerry's pivot toward physical AI and its critical role in automotive and robotics safety, with community members actively discussing upcoming growth potential and the company's positioning within the software-defined vehicle market.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is trending as investor focus intensifies on its strategic oncology pipeline acquisitions and long-term efforts to diversify revenue ahead of upcoming major drug patent expirations. Market participants are actively discussing the company's M&A potential, specifically regarding its ability to secure innovative cancer platforms to maintain its dominant market position.

KraneShares Trust - KraneShares CSI China Internet ETF

KraneShares CSI China Internet ETF

KraneShares CSI China Internet ETF (KWEB) is trending as investors debate the potential for a rebound in Chinese tech, driven by optimism regarding upcoming trade discussions and speculation about state-led AI infrastructure spending. The community is actively discussing the sharp divergence between US market highs and Chinese valuations, with many investors weighing the risks of regulatory pressure against the appeal of deep-value entry points in the sector.

Freeport-McMoRan, Inc. engages in the mining of copper, gold, and molybdenum. It operates through the following segments: U.S. Copper Mines, South America Operations, Indonesia Operations, Molybdenum Mines, U.S. Rod and Refining, Atlantic Copper, and Corporate and Other. The U.S. Copper Mines segment operates open-pit copper mines in Morenci, Bagdad, Safford, Sierrita, Miami in Arizona and Chino, and Tyrone in New Mexico. The South America Operations segment includes Cerro Verde in Peru and El Abra in Chile. The Indonesia Operations segment handles the operations of the Grasberg minerals district that produce copper concentrate containing significant quantities of gold and silver. The Molybdenum Mines segment includes the Henderson underground mine and Climax open pit mine, both in Colorado. The U.S. Rod and Refining segment consists of copper conversion facilities located in North America and includes refinery and rod mills. The Atlantic Copper segment smelts and refines copper concentrate and markets refined copper and precious metals in slimes. The Corporate and Other segment offers other mining and eliminations, oil and gas operations, and other corporate and elimination items. The company was founded by James R. Moffett on November 10, 1987, and is headquartered in Phoenix, AZ.

Freeport-McMoRan Inc

Freeport-McMoRan is trending as investors weigh potential shifts in US trade policy and geopolitical tensions against the structural long-term copper demand driven by AI infrastructure and electrification. The community is actively debating the stock's volatility and its role as a strategic domestic play in the face of evolving supply chain security policies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aurinia Pharmaceuticals is trending as investors monitor recent institutional accumulation and optimistic sentiment regarding the Phase 4 PRESERVE study, which is viewed as a strategic move to showcase the synergy of its primary drug with biologics. The community is actively discussing the potential for a buyout, debating the impact of the current patent litigation, and evaluating the strategic silence of leadership as a possible precursor to a future sale.

Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of +47.37% and -0.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and six months ended June 30, 2026 and provided an update on recent business progress. Financial Results Total Revenue: For the three and six months ended June 30, 2026, total revenue was $83.2 million and...

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates

NewAmsterdam Pharma Company N.V. (NAMS) delivered earnings and revenue surprises of -8.33% and -45.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Therapeutics (KPTI) Soars 5.3%: Is Further Upside Left in the Stock?

Karyopharm Therapeutics (KPTI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced the initiation of PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNIS and belimumab, obinutuzumab or anifrolumab in patients with lupus nephritis (ClinicalTrials.gov). Planned enrollment is approximately 150...

Aurinia (AUPH) Upgraded to Strong Buy: Here's Why

Aurinia (AUPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker 

Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.


5 Small Drug Stocks to Invest in Amid a Biotech Comeback

Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.

Aurinia (AUPH) Moves 6.5% Higher: Will This Strength Last?

Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Are Medical Stocks Lagging  Astellas Pharma (ALPMY) This Year?

Here is how Astellas Pharma Inc. (ALPMY) and Aurinia Pharmaceuticals (AUPH) have performed compared to their sector so far this year.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

AUPH Stock Sees Biggest Single-Day Drop In More Than 9 Months Despite Q1 Earnings Beat – Here’s What’s Spooking Investors

Equity

Bearish Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a winning week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

AUPHAurinia Pharmaceuticals Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest AUPH News